SA PRO
Free Account
Arcus Biosciences, Inc.RCUSNYSE
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 88% recommend buying.

Consensus Rating
Buy
17 analysts·Moderate coverage
88%
Rating Distribution
Strong Buy
00%
Buy
1588%
Hold
212%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 38% higher.

Bear Case
$20.00
-5%
Consensus
$29.00
+38%
Bull Case
$35.00
+66%
Price Range17 analysts
Low
Consensus
High
$20.00
$35.00
Current Target
Current Price
$21.04
Upside to Target
$7.96

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Jan 12, 2026Goldman Sachs
Arcus Biosciences upgraded to Buy from Neutral at Goldman Sachs
Target:$28.00
+31.5%from $21.30
Jan 8, 2026Morgan Stanley
Arcus Biosciences downgraded to Equal Weight from Overweight at Morgan Stanley
Target:$20.00
-13.8%from $23.20
Dec 12, 2025Truist Financial
Arcus Biosciences price target lowered to $30 from $39 at Truist
Target:$30.00
+34.7%from $22.27
Dec 12, 2025H.C. Wainwright
Arcus Biosciences price target raised to $32 from $28 at H.C. Wainwright
Target:$32.00
+44.5%from $22.15
Oct 30, 2025Goldman Sachs
Arcus Biosciences price target raised to $16 from $14 at Goldman Sachs
Target:$16.00
-22.5%from $20.64
Oct 29, 2025Wedbush
Arcus Biosciences price target raised to $35 from $33 at Wedbush
Target:$35.00
+72.5%from $20.29
Oct 29, 2025H.C. Wainwright
Arcus Biosciences price target raised to $28 from $24 at H.C. Wainwright
Target:$28.00
+40.8%from $19.88
Oct 7, 2025Truist Financial
Arcus Biosciences price target raised to $39 from $32 at Truist
Target:$39.00
+169.3%from $14.48
May 7, 2025Wells Fargo
Arcus Biosciences price target lowered to $26 from $29 at Wells Fargo
Target:$26.00
+220.2%from $8.12
Oct 24, 2024Citigroup
Arcus Biosciences price target raised to $46 from $38 at Citi
Target:$46.00
+164.1%from $17.41
Oct 21, 2024H.C. Wainwright
H.C. Wainwright Starts Arcus Biosciences (RCUS) at Neutral
Target:$20.00
+8.5%from $18.44
Oct 8, 2024Wells Fargo
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Target:$29.00
+60.4%from $18.08
Oct 8, 2024Morgan Stanley
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Target:$35.00
+93.6%from $18.08
Aug 9, 2024Bank of America Securities
Arcus Biosciences (RCUS) PT Lowered to $23 at BofA Securities
Target:$23.00
+68.0%from $13.69
Jul 8, 2024Barclays
Arcus Biosciences (RCUS) PT Lowered to $25 at Barclays
Target:$25.00
+78.6%from $14.00
Jun 24, 2024Truist Financial
Arcus Biosciences (RCUS) PT Lowered to $44 at Truist Securities
Target:$44.00
+167.5%from $16.45
Jun 4, 2024Barclays
Barclays Reiterates Overweight Rating on Arcus Biosciences (RCUS)
Target:$35.00
+116.7%from $16.15
Dec 20, 2022Citigroup
Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $42
Target:$42.00
+103.3%from $20.66
Nov 23, 2022Citigroup
Citigroup Maintains Buy on Arcus Biosciences, Lowers Price Target to $37
Target:$37.00
+37.0%from $27.00
May 11, 2022Wedbush
Arcus Biosciences price target lowered to $42 from $67 at Wedbush
Target:$42.00
+74.9%from $24.01

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance